Vertex Pharmaceuticals’ Suzetrigine: A Promising Opioid Alternative in Pain Management
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...
Hosted on MSN1d
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to Decline
Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $456 and keeps an Equal Weight rating on the ...
MyChesCo on MSN4d
Vertex, Inc. Sets Date for Q4 2024 Financial Results Announcement and Conference Call
Vertex, Inc. (NASDAQ: VERX) has announced plans to release its fourth quarter 2024 financial results on the morning of ...